These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

905 related items for PubMed ID: 23265714

  • 1. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
    Eckert C, von Stackelberg A, Seeger K, Groeneveld TW, Peters C, Klingebiel T, Borkhardt A, Schrappe M, Escherich G, Henze G.
    Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714
    [Abstract] [Full Text] [Related]

  • 2. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
    Eckert C, Henze G, Seeger K, Hagedorn N, Mann G, Panzer-Grümayer R, Peters C, Klingebiel T, Borkhardt A, Schrappe M, Schrauder A, Escherich G, Sramkova L, Niggli F, Hitzler J, von Stackelberg A.
    J Clin Oncol; 2013 Jul 20; 31(21):2736-42. PubMed ID: 23775972
    [Abstract] [Full Text] [Related]

  • 3. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
    Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, Barth A, Borkhardt A, Peters C, Handgretinger R, Sykora KW, Holter W, Kabisch H, Klingebiel T, von Stackelberg A, ALL-REZ BFM Study Group.
    J Clin Oncol; 2009 Jan 20; 27(3):377-84. PubMed ID: 19064980
    [Abstract] [Full Text] [Related]

  • 4. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A, Mann G, Panzer-Grümayer R, Röttgers S, Steiner M, König M, Csinady E, Dworzak MN, Seidel M, Janousek D, Möricke A, Reichelt C, Harbott J, Schrappe M, Gadner H, Haas OA.
    J Clin Oncol; 2008 Jun 20; 26(18):3046-50. PubMed ID: 18565891
    [Abstract] [Full Text] [Related]

  • 5. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U, Harms DO, Schlüter S, Jorch N, Spaar HJ, Nürnberger W, Völpel S, Gutjahr P, Schrappe M, Janka G, Kabisch H.
    Klin Padiatr; 2000 Jun 20; 212(4):169-73. PubMed ID: 10994545
    [Abstract] [Full Text] [Related]

  • 6. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.
    Bader P, Kreyenberg H, von Stackelberg A, Eckert C, Salzmann-Manrique E, Meisel R, Poetschger U, Stachel D, Schrappe M, Alten J, Schrauder A, Schulz A, Lang P, Müller I, Albert MH, Willasch AM, Klingebiel TE, Peters C.
    J Clin Oncol; 2015 Apr 10; 33(11):1275-84. PubMed ID: 25605857
    [Abstract] [Full Text] [Related]

  • 7. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?
    Balduzzi A, Di Maio L, Silvestri D, Songia S, Bonanomi S, Rovelli A, Conter V, Biondi A, Cazzaniga G, Valsecchi MG.
    Br J Haematol; 2014 Feb 10; 164(3):396-408. PubMed ID: 24422724
    [Abstract] [Full Text] [Related]

  • 8. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
    Sramkova L, Muzikova K, Fronkova E, Krejci O, Sedlacek P, Formankova R, Mejstrikova E, Stary J, Trka J.
    Pediatr Blood Cancer; 2007 Jan 10; 48(1):93-100. PubMed ID: 16521130
    [Abstract] [Full Text] [Related]

  • 9. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.
    Einsiedel HG, von Stackelberg A, Hartmann R, Fengler R, Schrappe M, Janka-Schaub G, Mann G, Hählen K, Göbel U, Klingebiel T, Ludwig WD, Henze G.
    J Clin Oncol; 2005 Nov 01; 23(31):7942-50. PubMed ID: 16258094
    [Abstract] [Full Text] [Related]

  • 10. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
    Paganin M, Zecca M, Fabbri G, Polato K, Biondi A, Rizzari C, Locatelli F, Basso G.
    Leukemia; 2008 Dec 01; 22(12):2193-200. PubMed ID: 18754029
    [Abstract] [Full Text] [Related]

  • 11. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.
    Tallen G, Ratei R, Mann G, Kaspers G, Niggli F, Karachunsky A, Ebell W, Escherich G, Schrappe M, Klingebiel T, Fengler R, Henze G, von Stackelberg A.
    J Clin Oncol; 2010 May 10; 28(14):2339-47. PubMed ID: 20385996
    [Abstract] [Full Text] [Related]

  • 12. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
    Tie LJ, Gu LJ, Song DL, Jiang LM, Xue HL, Tang JY, Dong L, Pan C, Chen J, Ye H, Wang YP, Chen J.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan 10; 26(1):6-9. PubMed ID: 15946500
    [Abstract] [Full Text] [Related]

  • 13. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.
    Sutton R, Shaw PJ, Venn NC, Law T, Dissanayake A, Kilo T, Haber M, Norris MD, Fraser C, Alvaro F, Revesz T, Trahair TN, Dalla-Pozza L, Marshall GM, O'Brien TA.
    Br J Haematol; 2015 Feb 10; 168(3):395-404. PubMed ID: 25312094
    [Abstract] [Full Text] [Related]

  • 14. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.
    van Dongen JJ, Seriu T, Panzer-Grümayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MA, Cazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WC, Riehm H, Bartram CR.
    Lancet; 1998 Nov 28; 352(9142):1731-8. PubMed ID: 9848348
    [Abstract] [Full Text] [Related]

  • 15. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D, Benetello A, Buldini B, Maglia O, Masera G, Conter V, Arico M, Biondi A, Gaipa G.
    J Clin Oncol; 2009 Nov 01; 27(31):5168-74. PubMed ID: 19805690
    [Abstract] [Full Text] [Related]

  • 16. ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia.
    Henze G, v Stackelberg A, Eckert C.
    Klin Padiatr; 2013 May 01; 225 Suppl 1():S73-8. PubMed ID: 23700062
    [Abstract] [Full Text] [Related]

  • 17. Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system.
    Harker-Murray PD, Thomas AJ, Wagner JE, Weisdorf D, Luo X, DeFor TE, Verneris MR, Dusenbery KE, MacMillan ML, Tolar J, Baker KS, Orchard PJ.
    Biol Blood Marrow Transplant; 2008 Jun 01; 14(6):685-92. PubMed ID: 18489994
    [Abstract] [Full Text] [Related]

  • 18. Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment.
    Eckert C, Hagedorn N, Sramkova L, Mann G, Panzer-Grümayer R, Peters C, Bourquin JP, Klingebiel T, Borkhardt A, Cario G, Alten J, Escherich G, Astrahantseff K, Seeger K, Henze G, von Stackelberg A.
    Leukemia; 2015 Aug 01; 29(8):1648-55. PubMed ID: 25748682
    [Abstract] [Full Text] [Related]

  • 19. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation.
    Zhao XS, Liu YR, Zhu HH, Xu LP, Liu DH, Liu KY, Huang XJ.
    Ann Hematol; 2012 Feb 01; 91(2):183-92. PubMed ID: 21710165
    [Abstract] [Full Text] [Related]

  • 20. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study.
    Yeoh AE, Ariffin H, Chai EL, Kwok CS, Chan YH, Ponnudurai K, Campana D, Tan PL, Chan MY, Kham SK, Chong LA, Tan AM, Lin HP, Quah TC.
    J Clin Oncol; 2012 Jul 01; 30(19):2384-92. PubMed ID: 22614971
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.